Artelo Biosciences, Inc.(ARTL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ARTL Artelo Biosciences, Inc.

盘前交易 09-30 06:22:56 EDT

4.07

-0.23

-5.35%

盘前3.97

-0.10-2.44%

06:15 EDT

最高4.30	最低4.05	成交量8.90万
今开4.20	昨收4.30	日振幅5.81%
总市值222.95万	流通市值222.80万	总股本54.78万
成交额36.80万	换手率16.25%	流通股本54.74万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ARTL","market":"US","secType":"STK","nameCN":"Artelo Biosciences, Inc.","latestPrice":4.07,"timestamp":1790712000000,"preClose":4.3,"halted":0,"volume":88958,"hourTrading":{"tag":"盘前","latestPrice":3.9708,"preClose":4.07,"latestTime":"06:15 EDT","volume":1008,"amount":4048.2802079999997,"timestamp":1790763350550,"change":-0.0992,"changeRate":-0.024373,"amplitude":0.039115},"delay":0,"changeRate":-0.05348837209302315,"floatShares":547422,"shares":547777,"eps":-102.41509,"marketStatus":"盘前交易","change":-0.23,"latestTime":"09-30 06:22:56 EDT","open":4.2,"high":4.3,"low":4.05,"amount":367967.11661200004,"amplitude":0.05814,"askPrice":4.34,"askSize":100,"bidPrice":3.9,"bidSize":899,"shortable":3,"etf":0,"ttmEps":-102.41509,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790775000000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":4.07,"preHourTrading":{"tag":"盘前","latestPrice":3.9708,"preClose":4.07,"latestTime":"06:15 EDT","volume":1008,"amount":4048.2802079999997,"timestamp":1790763350550,"change":-0.0992,"changeRate":-0.024373,"amplitude":0.039115},"postHourTrading":{"tag":"盘后","latestPrice":4.0555,"preClose":4.07,"latestTime":"19:56 EDT","volume":4235,"amount":25212.4036,"timestamp":1790726187320,"change":-0.0145,"changeRate":-0.003563,"amplitude":0.027027},"volumeRatio":0.01651827759628153},"requestUrl":"/m/hq/s/ARTL","defaultTab":"news","newsList":[{"id":"2671618294","title":"纳斯达克推出面向资本市场与财资业务的人工智能整合框架。","url":"https://stock-news.laohu8.com/highlight/detail?id=2671618294","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671618294?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:02","pubTimestamp":1790668962,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["VUSE","CPNQ","ARTL","FWD","ARTY","KOMP","MFIG","NEWZ","QQQJ","QQQA","MNQmain","TARK","AQGX","QQA","AIQU","IWLG","AIBU","GPIQ","QQQY","WPAI","AGIX","NBDS","BLGR","FTEC","GROZ","TECY","CWC","QID","DQJN","NQmain",".IXIC","QQQM","LCLG","QSWN","MVPS","QQQE","QLD","CHAT","TQQQ","AIFD","OGIG","PBOT","03086","NDX","GK","QDTE","ESLG","PSQ","FIVY","QTOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670452475","title":"AI狂潮硬扛“5%美债收益率”! 纳斯达克创新高强化“80/20”格局，华尔街重估股债比例","url":"https://stock-news.laohu8.com/highlight/detail?id=2670452475","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670452475?lang=zh_cn&edition=full","pubTime":"2026-09-26 14:46","pubTimestamp":1790405186,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ALTL","FFLG","FMTM","MAYU","SPHQ","MTUL","ARTL","QB","SPYT","HEQ","EDGE","OCDB","QTOC","MMAR","XNTK","AGIX","FEX","GSLC","DYNF","RECI","ESLG",".IXIC","ONEO","FTA","LDER","NDX","CHAT","EIM","IYY","BUFD","CAIE","RSEE","MSLC","PBSE","ILCB","SVOL","TRTY","GOVM","JULD","STRV","FFA","MRCP","VAIE","AESR","MBOX","PBJA","BUFT","SPXS","TPAY","XLUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669883488","title":"芯片股带飞纳斯达克创6月来新高，日经期指高开接力：日本股市明日补涨在即","url":"https://stock-news.laohu8.com/highlight/detail?id=2669883488","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669883488?lang=zh_cn&edition=full","pubTime":"2026-09-23 19:10","pubTimestamp":1790161807,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["JPN","SEIE","MFDX","PIEQ","IJUN","CIL","IMFL","SCHF","FENI","DDWM","TDI","VIDI","YSEP","XSEM","GSID","BBIN","GSJY","IOCT","JPAN","CEFA","VEA","ICPY","IBUF","QBIV","NDX","DWMF","ESLG","DMXF","ISEP","DTAN","TXUE","BUFY","FIVY","IVSI","ARTL","EFA","GROZ","OPPJ","QEFA","XW","RFDI","PDEV","DXJ","IDJN","EZJ","JDVI","PTIN","IVAL","ARLI","GIEQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668213849","title":"美股三大股指转跌，道指跌近0.5%，标普500指数跌0.2%，纳指跌0.03%，甲骨文、高通跌超3%。纳斯达克中国金龙指","url":"https://stock-news.laohu8.com/highlight/detail?id=2668213849","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668213849?lang=zh_cn&edition=full","pubTime":"2026-09-18 22:07","pubTimestamp":1789740438,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SPYM","PQV","AUGZ","RSST","SPXL","DAUG","MBCC","SPYB","FIVY","SSO","UPRO","MARW","GSPY","MAYP","NDX","PBMY","PQX","PMNV",".SPX","ARTL","MAYM","SPUU","SPYQ","CPSO","IVV","GPIX","SPDN","QQQ","SDS","SSS","SH","JNEU","SPY","FLJJ","SIXZ","BBUS","VOO","CPSD","AAUA","TQQQ","SPXS","IWLG","DLNV","SPYU","GROZ","PMJN","JULP","SQQQ","DFUS","FEBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195223082","title":"Artelo Biosciences宣布：Art27.13单药减重效果媲美司美格鲁肽，联合用药减重效果翻倍——非临床肥胖模型研究揭晓","url":"https://stock-news.laohu8.com/highlight/detail?id=1195223082","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195223082?lang=zh_cn&edition=full","pubTime":"2026-09-16 19:31","pubTimestamp":1789558271,"startTime":"0","endTime":"0","summary":"Artelo Biosciences, Inc.今日发布重磅消息：其研发的Art27.13在非临床肥胖模型研究中展现出令人瞩目的减重潜力。数据显示，该候选药物作为单药疗法时，其减重效果与司美格鲁肽不相上下；更值得关注的是，当Art27.13与司美格鲁肽联合使用时，减重效果竟实现了翻倍提升。Artelo Biosciences表示，公司将继续推进Art27.13的临床前研究，并计划尽快进入临床试验阶段，以进一步评估其在人类患者中的安全性和有效性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ARTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163249166","title":"Artelo Biosciences：Art27.13单药疗法在肥胖小鼠中实现体重减轻20%，效果与Semaglutide相当","url":"https://stock-news.laohu8.com/highlight/detail?id=1163249166","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163249166?lang=zh_cn&edition=full","pubTime":"2026-09-16 19:31","pubTimestamp":1789558270,"startTime":"0","endTime":"0","summary":"Artelo Biosciences宣布，其研发的候选药物Art27.13在单药治疗中展现出显著减重效果——在肥胖小鼠模型中，该疗法促使体重下降达20%。这一结果令人瞩目，因其疗效与目前市场上备受瞩目的GLP-1受体激动剂Semaglutide所达到的水平不相上下。此次公布的临床前数据，无疑为Artelo Biosciences在代谢疾病领域的布局增添了一抹亮色。Artelo Biosciences的管理层对此保持审慎乐观，并承诺将加速推进相关研究，以尽早惠及广大患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667063655","title":"锚定纳斯达克！Anthropic 冲刺创纪录 IPO，募资规模剑指 SpaceX","url":"https://stock-news.laohu8.com/highlight/detail?id=2667063655","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667063655?lang=zh_cn&edition=full","pubTime":"2026-09-14 08:07","pubTimestamp":1789344422,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据一位知情人士透露，Anthropic PBC 已选定纳斯达克作为其上市地点，此次潜在 IPO 有望创下历史纪录。　　知情人士称，这家 Claude 聊天机器人的开发商寻求在此次 IPO 中募集的资金规模与 SpaceX 相当甚至更高，IPO 最快可能于 10 月进行。　　按其当前业绩推算，Anthropic 的年化营收有望超过 650 亿美元，较去年年底的运行速率增长逾七倍。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260914/32368380.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["QQQE","TQQY","DXYZ","QQQA","QQQY","XOVR","ONEQ","SNK","LOFF","SPCH","TECS","QID","WSPC","QLD","FIVY","WARP","SPCU","QQQM","IWLG",".IXIC","QYLG","FTEC","SPCX","IYW","ARTL","UFO","PSQ","REDS","BLGR","SPAL","ESLG","QDTE","NQmain","159632","ORBX","SQQQ","03086","NDX","TQQQ","MARS","QQQ","GROZ","KCE","NVIW.SI","SPCF","LCLG","FRHC","IPOS","QQQJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664740899","title":"Variational 上线黄金与纳斯达克 100 互换市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2664740899","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664740899?lang=zh_cn&edition=full","pubTime":"2026-09-02 14:39","pubTimestamp":1788331162,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，Arbitrum 生态链上衍生品协议 Variational 宣布其互换交易（Swaps）市场上线，首批包括黄金（XAU）和纳斯达克 100 指数（US100）市场。互换交易与永续合约类似均可提供标的资产敞口，区别在于流动性来源及持仓费用：互换交易的持仓成本以美元借贷利率为基准，目前多头年化支付 4% 至 6%，空头年化收取 2% 至 3%，取代了波动较大的资金费率。Swaps 市场全程免收交易费用，初始未平仓合约限额约为每个市场 1000 万美元，团队计划未来数天内将限额提升至 5000 万美元以上，其初始协议可支持超过 10 亿美元的未平仓合约规模。团队表示，未来数月还将继续提高限额、上线更多互换与永续合约市场、推出交易 API，并推动实现全天候流动性。 ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2287087","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FAAR","OUNZ","DUST","GBUG","IAUM","QOmain","UGL","DZZ","GLTR","GCmain","159831","IAU","LCLG","JDST","JNUG","NDX","CEF","GROZ","ARTL","GDXY","AAAU","ESLG","FGDL","SGDM","IWLG","03086","UYM","FIVY","MGCmain","GDXU","SGOL","BAR","RING","GDX","BEGS","GLL","159632","PHYS","BTGD","02840","NQmain","DULL","1OZmain","DGP",".IXIC","SHNY","USG","GDXD","BLGR","XME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660287151","title":"奇点未来科技有限公司宣布，根据纳斯达克规则，以市价定价完成500万美元的注册直接发行。","url":"https://stock-news.laohu8.com/highlight/detail?id=2660287151","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660287151?lang=zh_cn&edition=full","pubTime":"2026-08-20 21:29","pubTimestamp":1787232563,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NQmain",".IXIC","PSQ","03034","07522","QQQE","SQQQ","NOCT","BLGR","QDTE","TQQQ","MNQmain","QQQM","QQQA","QID","NAPR","QQQY","QQQ","QQQX","NJUL","IWLG","QMAR","BK4007","ESLG","GROZ","QLD","03455","IYW","QYLG","NDX","07568","QDEC","03086","FTEC","GPIQ","LCLG","ARTL","QQQJ","FIVY","07261","09086","NJAN","JEPQ","09834","ONEQ","02834","NVIW.SI","TECS","TQQY","07266"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149704503","title":"Artelo Biosciences在日本获得Art27.13预期商业配方专利授权的核准通知","url":"https://stock-news.laohu8.com/highlight/detail?id=1149704503","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149704503?lang=zh_cn&edition=full","pubTime":"2026-08-20 21:00","pubTimestamp":1787230813,"startTime":"0","endTime":"0","summary":"Artelo Biosciences已成功获得日本专利局对其Art27.13预期商业配方专利权利要求发出的核准通知。这一关键进展标志着公司在国际知识产权布局上再下一城，为其核心候选药物的商业化道路扫清了重要障碍。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ARTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171932717","title":"Artelo宣布：评估Art27.13治疗青光眼的2期临床试验首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1171932717","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171932717?lang=zh_cn&edition=full","pubTime":"2026-08-10 20:54","pubTimestamp":1786366498,"startTime":"0","endTime":"0","summary":"Artelo Biosciences对外宣布，其针对新型候选药物Art27.13治疗青光眼的2期临床试验，已成功招募并入组了首位患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654188880","title":"纳斯达克100指数势将进入回调阶段对AI投资最终回报的担忧正在削弱对推动今年股市上涨的科技巨头的市场情绪。周二纳斯达克1","url":"https://stock-news.laohu8.com/highlight/detail?id=2654188880","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654188880?lang=zh_cn&edition=full","pubTime":"2026-07-28 22:04","pubTimestamp":1785247494,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CPNS","QBIG","QDTE","CPNJ","QLD","QMAR","QQQM","QCOC","NMAY","XMAG","QCJA","QMMY","QQQG","QSWN","DQJN","ARTL","IQQ","IWLG","QHDG","QID","PQAP","QCJL","QXQ","YQQQ","QQMG","AIPO","QQQE","QTR","QTOC","QYLE","VTHR","PSQ","QCLR","NDX","FIVY","QYLG","QDTY","QSIX","PTNQ","BLGR","QRMI","QB","QQQA","GROZ","QQQW",".IXIC","QQQT","ROCQ","QQQX","QGRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118062181","title":"Artelo Biosciences公布骨关节炎非临床研究结果，支持Art26.12成为慢性疼痛潜在首创新疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1118062181","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118062181?lang=zh_cn&edition=full","pubTime":"2026-07-16 20:55","pubTimestamp":1784206549,"startTime":"0","endTime":"0","summary":"Artelo Biosciences公布了一项非临床骨关节炎研究的结果，该研究支持其候选药物Art26.12成为治疗慢性疼痛的潜在首创新疗法。这项研究为Art26.12的开发提供了重要的临床前数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ARTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183709261","title":"Artelo 生物科学 - Art26.12 在非临床骨关节炎研究中显示疗效与萘普生相当","url":"https://stock-news.laohu8.com/highlight/detail?id=1183709261","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183709261?lang=zh_cn&edition=full","pubTime":"2026-07-16 20:48","pubTimestamp":1784206121,"startTime":"0","endTime":"0","summary":"Artelo Biosciences, Inc. 宣布，其候选药物 Art26.12 在一项非临床骨关节炎研究中，展现出了与常用镇痛抗炎药萘普生（Naproxen）相当的疗效。这一积极发现为该公司针对疼痛管理的新药研发管线注入了新的动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ARTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651938499","title":"纳斯达克金龙中国指数收涨2.92%，热门中概股普涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2651938499","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651938499?lang=zh_cn&edition=full","pubTime":"2026-07-16 05:12","pubTimestamp":1784149964,"startTime":"0","endTime":"0","summary":"当地时间7月15日，纳斯达克金龙中国指数收涨2.92%，热门中概股普涨，名创优品涨超9%，腾讯控股涨超5%，阿里巴巴、哔哩哔哩涨超4%，小鹏集团涨超3%，唯品会、爱奇艺、理想汽车、拼多多涨超2%，百度、网易涨超1%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607163807921878.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607163807921878.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ASHS","KWEB","CNQQ","ONEQ","TECS","ASHR","FIVY","CHAU","IYW","KCAI","MCHI","KALL","NBCE","CQQQ","QLD","NDX","ARTL","QYLG","QQQA","QQQJ","QDTE","FXI","QQQ","DRAG","JCHI","CWEB","PCCE","SQQQ","159632","PSQ","JEPQ",".IXIC","TQQQ","QID","TQQY","YANG","FTEC","QQQM","TTTN","MCH","IWLG","NVIW.SI","GPIQ","GROZ","03086","QQQE","HXC","LCLG","YINN","FLCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152535810","title":"Artelo Biosciences中期数据：1300微克/日剂量下体重、瘦体重、活动能力改善且安全性良好","url":"https://stock-news.laohu8.com/highlight/detail?id=1152535810","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152535810?lang=zh_cn&edition=full","pubTime":"2026-07-13 21:04","pubTimestamp":1783947885,"startTime":"0","endTime":"0","summary":"Artelo Biosciences公布的中期试验结果显示，在每日剂量高达1300微克的用药方案下，受试者的体重、瘦体重（肌肉量）以及活动能力均呈现出积极改善趋势，同时治疗耐受性良好，未出现重大安全性问题。这些数据为该公司相关候选药物的进一步开发提供了支持性证据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650185418","title":"募资265亿美元！SK海力士(SKHY.US)今晚登陆纳斯达克 能否摆脱“韩国折价”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2650185418","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650185418?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:54","pubTimestamp":1783673644,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，韩国芯片巨头SK海力士将于周五登陆纳斯达克，本次上市将检验该股能否摆脱长期存在的 “韩国折价” 困境。此次SK海力士通过发行美国存托凭证，将直接对接全球规模最庞大的资本市场，业内专家认为此举可能收窄 “韩国折价” 。LSEG数据显示，美光今年股价飙升近250%，SK海力士则上涨了240%。募资265亿美元，更大价值是接轨美资市场SK海力士本次ADR发行定价149美元，募资规模约265亿美元，有望刷新美股外资企业IPO纪录。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465878.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["QQQM","QQQJ","FIVY","TQQY","GROZ","EEMO","EDZ","QQQE","DRAL","07266","FTEC","QDEC","09086","LCLG","QQQY","TECS","QYLG","IWLG",".IXIC","NJUL","QQQA","QID","NDX","159632","NOCT","SQQQ","MNQmain","ONEQ","NQmain","QQQ","QQQX","02834","07568","QLD","03034","PSQ","03086","JEPQ","07261","09834","GPIQ","NVIW.SI","TQQQ","IYW","NJAN","SKHY","SKHYV","QDTE","RAM","ARTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154960188","title":"Artelo Biosciences公布新数据，支持Art26.12成为治疗脊髓损伤相关慢性疼痛的潜在同类首创疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1154960188","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154960188?lang=zh_cn&edition=full","pubTime":"2026-07-01 20:47","pubTimestamp":1782910073,"startTime":"0","endTime":"0","summary":"Artelo Biosciences宣布了新的研究数据，这些数据有力支持其候选药物Art26.12有望成为治疗脊髓损伤所致慢性疼痛的潜在“同类首创”疗法。新公布的信息进一步验证了该药物的作用机制与临床前疗效，为其后续开发路径提供了关键支撑。慢性疼痛是脊髓损伤后常见的严重并发症，目前治疗选择有限且常伴随显著副作用，因此存在巨大的未满足医疗需求。Art26.12以其新颖的作用靶点，旨在从根源上调控疼痛信号通路，可能为患者带来全新的治疗希望。公司表示，这些积极数据将指导下一阶段的临床开发计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ARTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647757553","title":"霍尼韦尔宇航完成从霍尼韦尔科技分拆，正式在纳斯达克挂牌交易。","url":"https://stock-news.laohu8.com/highlight/detail?id=2647757553","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647757553?lang=zh_cn&edition=full","pubTime":"2026-06-29 19:07","pubTimestamp":1782731256,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","ARTL","BK4588","LU0683600562.USD","IE00B1BXHZ80.USD","BK4585","BK4206","LU0942090050.USD","LU0787776722.HKD","LU0868494708.USD","BK4550","BK4602","HON","BK4534","LU0868494617.USD","IE0034235188.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646035678","title":"纳斯达克 100 指数期货在美国经济数据公布后涨至盘中高位","url":"https://stock-news.laohu8.com/highlight/detail?id=2646035678","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646035678?lang=zh_cn&edition=full","pubTime":"2026-06-25 20:34","pubTimestamp":1782390881,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据 Gate 行情数据显示，纳斯达克 100 指数期货在美国经济数据公布后涨至盘中高位。 ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2273624","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IEI","DBND","IYW","VCIT","VGLT","GOLY","JEPQ","TBIL","BOND","ZROZ","NVIW.SI","DRV",".IXIC","QQQA","ARTL","IYR","MINT","EDV","03086","XLRE","MNQmain","DRN","ITB","NAIL","TQQQ","XRT","QQQY","ONEQ","VCSH","QLD","XHB","GOVT","GBIL","BSV","159632","NDX","NQmain","QDTE","TYO","SCHO","UBT","USHY","PBDC","QQQ","XLP","FGBXmain","TBT","VDC","DBA","SCHH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.artelobio.com","stockEarnings":[{"period":"1week","weight":-0.0193},{"period":"1month","weight":-0.3176},{"period":"3month","weight":-0.5889},{"period":"6month","weight":-0.9358},{"period":"1year","weight":-0.9742},{"period":"ytd","weight":-0.8764}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":-0.0067},{"period":"3month","weight":0.0247},{"period":"6month","weight":0.1652},{"period":"1year","weight":0.1515},{"period":"ytd","weight":0.1207}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Artelo Biosciences, Inc.于2011年5月2日在内华达州注册成立。该公司是一家临床生物制药公司，致力于开发和商业化旨在调节内源性信号通路的治疗方法，包括内源性大麻素系统（“ ECS”），形成整个身体生化通信网络的一系列受体和神经递质。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.048793},{"month":2,"riseRate":0.375,"avgChangeRate":0.02148},{"month":3,"riseRate":0.25,"avgChangeRate":0.078441},{"month":4,"riseRate":0.25,"avgChangeRate":-0.122994},{"month":5,"riseRate":0.375,"avgChangeRate":-0.068022},{"month":6,"riseRate":0.25,"avgChangeRate":0.069717},{"month":7,"riseRate":0.25,"avgChangeRate":-0.107792},{"month":8,"riseRate":0,"avgChangeRate":-0.140155},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.131254},{"month":10,"riseRate":0.125,"avgChangeRate":-0.187173},{"month":11,"riseRate":0.375,"avgChangeRate":-0.029503},{"month":12,"riseRate":0.75,"avgChangeRate":0.010567}],"exchange":"NASDAQ","name":"Artelo Biosciences, Inc.","nameEN":"Artelo Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Artelo Biosciences, Inc.(ARTL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Artelo Biosciences, Inc.(ARTL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Artelo Biosciences, Inc.,ARTL,Artelo Biosciences, Inc.股票,Artelo Biosciences, Inc.股票老虎,Artelo Biosciences, Inc.股票老虎国际,Artelo Biosciences, Inc.行情,Artelo Biosciences, Inc.股票行情,Artelo Biosciences, Inc.股价,Artelo Biosciences, Inc.股市,Artelo Biosciences, Inc.股票价格,Artelo Biosciences, Inc.股票交易,Artelo Biosciences, Inc.股票购买,Artelo Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Artelo Biosciences, Inc.(ARTL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Artelo Biosciences, Inc.(ARTL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}